Literature DB >> 17494097

Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment.

Stephanie T Page1, Thomas F Kalhorn, William J Bremner, Bradley D Anawalt, Alvin M Matsumoto, John K Amory.   

Abstract

Male hormonal contraceptive regimens function by suppressing gonadotropin secretion, resulting in a dramatic decrease in testicular androgen biosynthesis and spermatogenesis. Animal studies suggest that persistent intratesticular (iT)-androgen production has a stimulatory effect on spermatogenesis in the setting of gonadotropin suppression. We hypothesized that men with incompletely suppressed spermatogenesis (>1,000,000 sperm/mL) during male hormonal contraceptive treatment would have higher iT-androgen concentrations than men who achieved severe oligospermia (<or=1,000,000 sperm/mL). Twenty healthy men ages 18-55 years enrolled in a 6-month male contraceptive study of transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) with or without the gonadotropin releasing hormone (GnRH) antagonist acyline (300 microg/kg subcutaneously every 2 weeks for 12 weeks) were studied. During the 24th week of treatment, subjects underwent fine needle aspirations of the testes and iT-T and iT-dihydrotestosterone (iT-DHT) were measured in testicular fluid by liquid chromatography-tandem mass spectrometry. All men dramatically suppressed spermatogenesis; 15 of 20 men were severely oligospermic, and 5 of 20 suppressed to 1.5 million-3.2 million sperm per milliliter. In all subjects, mean iT-T and iT-DHT concentrations were 35 +/- 8 and 5.1 +/- 0.8 nmol/L. IT-androgen concentrations did not significantly differ in men who did and did not achieve severe oligospermia (P = .41 for iT-T; P = .18 for iT-DHT). Furthermore, there was no significant correlation between iT-T or iT-DHT and sperm concentration after 24 weeks of treatment. In this study of prolonged gonadotropin suppression induced by male hormonal contraceptive treatment, differences in iT-androgens did not explain differences in spermatogenesis. Additional studies to identify factors involved in persistent spermatogenesis despite gonadotropin suppression are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17494097     DOI: 10.2164/jandrol.107.002790

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  22 in total

1.  The effect of gonadotropin withdrawal and stimulation with human chorionic gonadotropin on intratesticular androstenedione and DHEA in normal men.

Authors:  M Y Roth; S T Page; K Lin; B D Anawalt; A M Matsumoto; B Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial.

Authors:  Mara Y Roth; Grace Shih; Niloufar Ilani; Christina Wang; Stephanie T Page; William J Bremner; Ronald S Swerdloff; Regine Sitruk-Ware; Diana L Blithe; John K Amory
Journal:  Contraception       Date:  2014-06-02       Impact factor: 3.375

3.  Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency.

Authors:  M Y Roth; S T Page; K Lin; B D Anawalt; A M Matsumoto; C N Snyder; B T Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

4.  Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Authors:  Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

5.  Serum LH correlates highly with intratesticular steroid levels in normal men.

Authors:  Mara Y Roth; K Lin; J K Amory; A M Matsumoto; B D Anawalt; C N Snyder; T F Kalhorn; W J Bremner; S T Page
Journal:  J Androl       Date:  2009-09-24

6.  Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.

Authors:  Bruce Montgomery; Peter S Nelson; Robert Vessella; Tom Kalhorn; David Hess; Eva Corey
Journal:  BMC Cancer       Date:  2010-05-28       Impact factor: 4.430

7.  Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial.

Authors:  Mara Y Roth; Kat Lin; Katrine Bay; John K Amory; Bradley D Anawalt; Alvin M Matsumoto; Brett T Marck; William J Bremner; Stephanie T Page
Journal:  Fertil Steril       Date:  2012-10-03       Impact factor: 7.329

8.  Complete sperm suppression in rats with dienogest plus testosterone undecanoate is facilitated through apoptosis in testicular cells.

Authors:  Rekha Meena; Man Mohan Misro; Debidas Ghosh
Journal:  Reprod Sci       Date:  2012-11-30       Impact factor: 3.060

9.  Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole.

Authors:  M Y Roth; J J S Nya-Ngatchou; K Lin; S T Page; B D Anawalt; A M Matsumoto; B T Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

10.  Effects of benzo(a)pyrene on intra-testicular function in F-344 rats.

Authors:  Anthony E Archibong; Aramandla Ramesh; Mohammad S Niaz; Cynthia M Brooks; Shannon I Roberson; Donald D Lunstra
Journal:  Int J Environ Res Public Health       Date:  2008-03       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.